CDC’s Tuberculosis Trials Consortium (TBTC) has recently launched the CRUSH-TB trial, which aims to identify new combinations of drugs to shorten treatment of active TB disease. Kelly Dooley, MD, PhD, MPH, Director, Division of Infectious Diseases, is a Protocol Chair for this new study.
Read more from CDC’s TB Notes newsletter:
https://www.cdc.gov/tb/publications/newsletters/notes/tbn_23/tbnotes-4.htm
“CDC’s TBTC launched an international clinical trial, Combination Regimens for Shortening Tuberculosis Treatment, or CRUSH-TB, to identify new combinations of drugs to shorten treatment of TB disease. These new regimens may improve drug tolerability and minimize drug interactions, giving healthcare providers more options to treat TB disease and completion of treatment. The trial compares the effectiveness and safety of 4-month bedaquiline, moxifloxacin, and pyrazinamide-based regimens to the standard of care 6-month regimen among patients with drug-susceptible pulmonary TB disease.
CRUSH-TB aims to enroll at least 288 participants from international TBTC sites over the next year. The study will randomly assign participants into one of three different study groups. The participants will know which TB treatment regimen they receive. The adaptive study design allows the researchers to add study groups to the trial to assess new TB treatment regimens. The trial will include a diverse group of participants including, children 12 years of age or older and people with human immunodeficiency virus (HIV).
CDC’s cutting-edge research uses domestic experiences to strengthen global TB elimination efforts and inform new treatment guidelines and recommendations. For CRUSH-TB, TBTC builds on the success of an international phase 3 clinical trial conducted with the National Institutes of Health-sponsored AIDS Clinical Trials Group. The results from that trial informed interim guidance for a 4-month treatment regimen to treat drug-susceptible pulmonary TB disease.”
